Novel inhibitors of the αvβ3 integrin-lead identification strategy

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4832-4835

  Elliot, David ^a   Henshaw, Eleanor ^a   MacFaul, Philip A ^a   Morley, Andrew D ^a   Newham, Peter ^a   Oldham, Keith ^a   Page, Ken ^a   Rankine, Neil ^a   Sharpe, Paul ^a   Ting, Attilla ^a   Wood, Christine M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Inhibitor; Integrin; Lead identification

Indexed keywords

AROMATIC AMIDE; RECEPTOR BLOCKING AGENT; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; BINDING SITE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; METABOLISM; MOLECULAR LIBRARY;

ANIMALS; BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; INTEGRIN ALPHAVBETA3; OLIGOPEPTIDES; RATS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67749120487     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.041     Document Type: Article

References (15)

1. Hynes R.O. Cell 110 (2002) 673
2. Cai W., and Chen X. Anticancer Agents Med. Chem. 6 (2006) 407
3. Nakamura I., Duong l.T., Rodan S.B., and Rodan G.A. J. Bone Miner. Metab. 25 (2007) 337
4. Wilder R.L. Ann. Rheum. Dis. 61 Suppl 2 (2002) ii96
5. Coleman P.J., and Duong L.T. Expert Opin. Therapeutic Patent 12 (2002) 1009
6. Henry C., Moitessier N., and Chapleur Y. Mini-Rev. Med. Chem. 2 (2002) 531
7. Jones R.C.F., and Dickson J. J. Pept. Sci. 6 (2000) 621
8. Kubota D., Ishikawa M., Yamamoto M., Murakami S., Hachisu M., Katano K., and Ajito K. Bioorg. Med. Chem. 14 (2006) 2089
9. Duggan M.E., Duong L.T., Fisher J.E., Hamill T.G., Hoffman W.F., Huff J.R., Ihle N.C., Leu C.-T., Nagy R.M., Perkins J.J., Rodan S.B., Wesolowski G., Whitman D.B., Zartman A.E., Rodan G.A., and Hartman G.D. J. Med. Chem. 43 (2000) 3736
10. Models of the binding modes of compounds 18, 25 and 43 with αvβ3 were generated from the RCSB (home.rcsb.org) Protein Data Bank (www.rcsb.org/pdb/home/home.do), with entry reference code 1L5G (Ref. 13) using the Maestro molecular modeling program. The models were docked using Glide and then energy-minimized using OPLS 2005 force field. Glide, Maestro and MarcoModel were licensed from Schrödinger, LGG (www.schrodinger.com).
11. Xiao T., Takagi J., Coller B.S., Wang J.-H., and Springer T.A. Nature (2004) 59
12. Since completion of the work described above, a re-refinement of the L-739758 in αiiβ3a complex has been deposited in the RCSB PDB with Refcode: 2vc2 replacing the previous version Refcode: 1TY7 (the coordinates are still available). There are subtle difference observed between the two versions, but this did not impact significantly on our findings and our strategy going into Lead Optimization.
13. Xiong J.-P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., and Arnaout M.A. Science 296 (2002) 151
14. Ishikawa M., Hiraiwa Y., Kubota D., Tsushima M., Watanabe T., Murakami S., Ouchi S., and Ajito K. Bioorg. Med. Chem. 14 (2006) 2131
15. Unpublished AstraZeneca data.